1. CMU Intellectual Repository

Browsing by Author Lerato Mohapi

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 8 of 8
Issue DateTitleAuthor(s)
15-Oct-2015Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis PreventionAnthony T. Podany; Yajing Bao; Susan Swindells; Richard E. Chaisson; Janet W. Andersen; Thando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A. Benson; Peter Kim; Courtney V. Fletcher
9-Jul-2020An Evaluation of Baseline Kidney Function in the REPRIEVE Trial of Pitavastatin in Human Immunodeficiency VirusEdgar T. Overton; Amy Kantor; Kathleen V. Fitch; Paul Muntner; Khuanchai Supparatpinyo; Mosepele Mosepele; Lerato Mohapi; Sandra Wagner Cardoso; Sandesh Patil; Marcus V.G. de Lacerda; Grace McComsey; Judith A. Aberg; Pamela S. Douglas; Steven K. Grinspoon; Heather Ribaudo; Christina M. Wyatt
14-Mar-2019One month of rifapentine plus isoniazid to prevent HIV-related TuberculosisSusan Swindells; Ritesh Ramchandani; Amita Gupta; Constance A. Benson; Jorge Leon-Cruz; Noluthando Mwelase; Marc A. Jean Juste; Javier R. Lama; Javier Valencia; Ayotunde Omoz-Oarhe; Khuanchai Supparatpinyo; Gaerolwe Masheto; Lerato Mohapi; Rodrigo O. Da Silva Escada; Sajeeda Mawlana; Peter Banda; Patrice Severe; James Hakim; Cecilia Kanyama; Deborah Langat; Laura Moran; Janet Andersen; Courtney V. Fletcher; Eric Nuermberger; Richard E. Chaisson
1-Jan-2020Pharmacogenetic interactions of rifapentine plus isoniazid with efavirenz or nevirapineDavid W. Haas; Anthony T. Podany; Yajing Bao; Susan Swindells; Richard E. Chaisson; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Constance A. Benson; Paxton Baker; Courtney V. Fletcher
1-Sep-2022Population Pharmacokinetic Modeling and Simulation of Rifapentine Supports Concomitant Antiretroviral Therapy with Efavirenz and Non-Weight Based DosingMichelle M. Pham; Anthony T. Podany; Noluthando Mwelase; Khuanchai Supparatpinyo; Lerato Mohapi; Amita Gupta; Wadzanai Samaneka; Ayotunde Omoz-Oarhe; Deborah Langat; Constance A. Benson; Richard E. Chaisson; Susan Swindells; Courtney V. Fletcher
1-Mar-2022Safety and immunogenicity of V114, a 15-valent pneumococcal conjugate vaccine, in adults living with HIVLerato Mohapi; Yvett Pinedo; Olayemi Osiyemi; Khuanchai Supparatpinyo; Winai Ratanasuwan; Jean Michel Molina; Ron Dagan; Gretchen Tamms; Tina Sterling; Ying Zhang; Alison Pedley; Jon Hartzel; Yanqing Kan; Kim Hurtado; Luwy Musey; Jakub K. Simon; Ulrike K. Buchwald
1-Sep-2019Third-line antiretroviral therapy in low-income and middle-income countries (ACTG A5288): a prospective strategy studyBeatriz Grinsztejn; Michael D. Hughes; Justin Ritz; Robert Salata; Peter Mugyenyi; Evelyn Hogg; Linda Wieclaw; Robert Gross; Catherine Godfrey; Sandra W. Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Faesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Anchalee Avihingsanon; Breno R. Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T. Schooley; John W. Mellors; Carole L. Wallis; Ann C. Collier; B. Grinsztejn; P. N. Mugyenyi; A. Collier; R. Salata; C. Godfrey; E. Hogg; M. Hughes; J. Ritz; L. Wieclaw; T. Sise; J. W. Mellors; C. Wallis; C. V. Fletcher; M. Gandhi; R. Gross; R. T. Schooley; R. Walensky; M. van Schalkwyk; S. Faesen; R. Mngqibisa; J. Valencia; E. Montalban; N. Kumarasamy; C. Kanyama; S. W. Cardoso; B. R. Santos; B. Mansfield; H. Mugerwa; B. W. Ndege; R. Secours; W. Samaneka; D. Kadam; V. Mave; M. Makanga; S. N. Fontain; P. Sugandhavesa; A. Avihingsanon; L. Nakibuuka; H. Nassolo; P. Anthony; V. Kulkarni; M. Nsubuga; J. van Wyk; J. Rooney; Y. van Delft; R. Leavitt; R. Luk; A. Benns; L. Hovind; A. Shahkolahi
1-Jun-2022Third-line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource-limited settings: ACTG A5288 strategy trialAnchalee Avihingsanon; Michael D. Hughes; Robert Salata; Catherine Godfrey; Caitlyn McCarthy; Peter Mugyenyi; Evelyn Hogg; Robert Gross; Sandra W. Cardoso; Aggrey Bukuru; Mumbi Makanga; Sharlaa Badal-aesen; Vidya Mave; Beatrice Wangari Ndege; Sandy Nerette Fontain; Wadzanai Samaneka; Rode Secours; Marije Van Schalkwyk; Rosie Mngqibisa; Lerato Mohapi; Javier Valencia; Patcharaphan Sugandhavesa; Esmelda Montalban; Cornelius Munyanga; Maganizo Chagomerana; Breno R. Santos; Nagalingeswaran Kumarasamy; Cecilia Kanyama; Robert T. Schooley; John W. Mellors; Carole L. Wallis; Ann C. Collier; Beatriz Grinsztejn
Showing results 1 to 8 of 8